



Publikationsliste - Prof. Dr. C. Bremer:

Originalarbeiten, Übersichtsartikel und Fallberichte

1. Helfen A, Große Hokamp N, Geyer C, Heindel W, **Bremer C**, Vogl T, Höltke C, Masthoff M, Barczyk-Kahlert K, Roth J, Wildgruber M, Eisenblaetter M.
Target-Specific Imaging of Cathepsin and S100A8/A9 Reflects Specific Features of Malignancy and Enables Estimation of Tumor Malignancy.
Mol Imaging Biol. 2019 May 16. doi: 10.1007/s11307-019-01370-1 [Epub ahead of print]
2. Höink A, Persigehl T, Kwiecien R, Balthasar M, Mesters R, Berdel W, Heindel W, **Bremer C**, Schwöppe C.
Gadofosveset-enhanced MRI as simple surrogate parameter for real-time evaluation of the initial tumour vessel infarction by retargeted tissue factor tTF-NGR.
Oncol Lett. 2019 Jan;17(1):270-280. doi: 10.3892/ol.2018.9638. Epub 2018 Oct 29
3. Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, Findlay M, Robinson B, Jackson C, Strickland A, GebSKI V, Van Buskirk M, Zhao H, van Hazel G; SIRFLOX and FOXFIRE Global Trial Investigators
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies.
Clin Colorectal Cancer. 2018 Dec;17(4):e617-e629. doi: 10.1016/j.clcc.2018.06.001. Epub 2018 Jun 12
4. Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, GebSKI V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA.
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug
5. Becker A, Große Hokamp N, Zenker S, Flores-Borja F, Barczyk K, Varga G, Roth J, Geyer C, Heindel W, **Bremer C**, Vogl T, Eisenblaetter M.
Optical in vivo imaging of the alarmin S100A9 in tumor lesions allows for estimation of the individual malignant potential by evaluation of tumor-host cell interaction.
J Nucl Med. 2015 Mar;56(3):450-6
6. Stange R, Sahin H, Wieskötter B, Persigehl T, Ring J, **Bremer C**, Raschke MJ, Vieth V.
In vivo monitoring of angiogenesis during tendon repair: a novel MRI-based technique in a rat patellar tendon model.
Knee Surg Sports Traumatol Arthrosc. 2015 Aug;23(8):2433-9
7. Vogl T, Eisenblätter M, Völler T, Zenker S, Hermann S, van Lent P, Faust A, Geyer C, Petersen B, Roebrock K, Schäfers M, **Bremer C**, Roth J
Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity.
Nat Commun. 2014 Aug 6;5:4593



8. Schmidt R, Nippe N, Strobel K, Masthoff M, Reifschneider O, Castelli DD, Höltke C, Aime S, Karst U, Sunderkötter C, Bremer C, Faber C.
Highly shifted proton MR imaging: cell tracking by using direct detection of paramagnetic compounds.
Radiology. 2014 Sep;272(3):785-95
9. Alsibai W, Hahnenkamp A, Eisenblätter M, Riemann B, Schäfers M, **Bremer C**, Haufe G, Höltke C.
Fluorescent non-peptidic RGD mimetics with high selectivity for $\alpha v \beta 3$ vs $\alpha IIb \beta 3$ integrin receptor: novel probes for in vivo optical imaging.
J Med Chem. 2014 Dec 11;57(23):9971-82
10. Hahnenkamp A, Alsibai W, **Bremer C**, Höltke C.
Optimizing the bioavailability of small molecular optical imaging probes by conjugation to an albumin affinity tag.
J Control Release. 2014 Jul 28;186:32-40
11. Persigehl T, Ring J, **Bremer C**, Heindel W, Holtmeier R, Stypmann J, Claesener M, Hermann S, Schäfers M, Zerbst C, Schliemann C, Mesters RM, Berdel WE, Schwöppe C.
Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
Angiogenesis. 2014 Jan;17(1):235-46
12. Persigehl T, Ring J, Budny T, Hahnenkamp A, Stoeppeler S, Schwartz LH, Spiegel HU, Heindel W, Remmele S, **Bremer C**.
Vessel size imaging (VSI) by robust magnetic resonance (MR) relaxometry: MR-VSI of solid tumors in correlation with immunohistology and intravital microscopy.
Mol Imaging. 2013 Oct;12(7):1-11
13. Hahnenkamp A, Schäfers M, **Bremer C**, Höltke C.
Design and synthesis of small-molecule fluorescent photoprobes targeted to aminopeptidase N (APN/CD13) for optical imaging of angiogenesis.
Bioconjug Chem. 2013 Jun 19;24(6):1027-38
14. Hillen J, Geyer C, Heitzmann M, Beckmann D, Krause A, Winkler I, Pavenstädt H, **Bremer C**, Pap T, Korb-Pap A.
Structural cartilage damage attracts circulating rheumatoid arthritis synovial fibroblasts into affected joints.
Arthritis Res Ther. 2017 Feb 28;19(1):40. doi: 10.1186/s13075-017-1245-9
15. Larmann J, Frenzel T, Schmitz M, Hahnenkamp A, Demmer P, Immenschuh S, Tietge UJ, Bremer C, Theilmeier G
In vivo fluorescence-mediated tomography imaging demonstrates atorvastatin-mediated reduction of lesion macrophages in ApoE^{-/-} mice.
Anesthesiology. 2013 Jul;119(1):129-41
16. Waschkau B, Faust A, Schäfers M, Bremer C
Performance of a new fluorescence-labeled MMP inhibitor to image tumor MMP activity in vivo in comparison to an MMP-activatable probe.
Contrast Media Mol Imaging. 2013 Jan-Feb;8(1):1-11
17. Neesse A, Hahnenkamp A, Griesmann H, Buchholz M, Hahn SA, Maghnouj A, Fendrich V, Ring J, Sipos B, Tuveson DA, **Bremer C**, Gress TM, Michl P
Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions
GUT, 2013 Jul;62(7):1034-43



18. Hischemöller A, Walter C, Weiler V, Hummel H, Thepen T, Huhn M, Barth S, Hoheisel W, Köhler K, Dimova-Landen D, **Bremer C**, Haase M, Waldeck J
Labeling of anti-MUC-1 binding single chain Fv fragments to surface modified upconversion nanoparticles for an in vivo molecular imaging proof of principle approach.
Int J Mol Sciences. 2012;13(4):4153-67
19. Larmann J, Frenzel T, Schmitz M, Hahnenkamp A, Demmer P, Immenschuh S, Tietge U, **Bremer C**, Theilmeier G
In Vivo Fluorescence-mediated Tomography Imaging Demonstrates Atorvastatin Mediated Reduction of Lesion Macrophages in ApoE^{-/-} Mice.
Anesthesiology. 2013 Jul; 119(1):129-41
20. Büther K, Compeer MG, De Mey JG, Schober O, Schäfers M, **Bremer C**, Riemann B, Höltke C.
Assessment of Endothelin-A Receptor Expression in Subcutaneous and Orthotopic Thyroid Carcinoma Xenografts in Vivo Employing Optical Imaging Methods.
Endocrinology. 2012 Jun;153(6):2907-18
21. Poellinger A, Persigehl T, Mahler M, Bahner M, Ponder SL, Diekmann F, **Bremer C**, Moesta T.
Near-infrared imaging of the breast using omocyanine as a fluorescent dye: results of a placebo-controlled, clinical, multicenter trial.
Invest Radiol. 2011 Nov;46(11):697-704
22. Ring J, Persigehl T, Remmele S, Heindel W, Dahnke H, **Bremer C**.
Monitoring of Bevacizumab-Induced Antiangiogenic Treatment Effects By "Steady State" Ultrasmall Superparamagnetic Iron Oxide Particles Magnetic Resonance Imaging Using Robust Multiecho ΔR_2^* Relaxometry.
Invest Radiol. 2011 May;46(5):326-30
23. Remmele S, Ring J, S negas J, Heindel W, Mesters RM, **Bremer C**, Persigehl T.
Concurrent MR blood volume and vessel size estimation in tumors by robust and simultaneous $\Delta R(2)$ and $\Delta R(2) * \text{quantification}$.
Magn Reson Med. 2011 Jul;66(1):144-53
24. Larmann J, Frenzel T, Hahnenkamp A, Herzog C, Lorenz A, Steinbicker AU, Calmer S, Harendza T, Schmitz M, Echtermeyer F, Hildebrand R, **Bremer C**, Theilmeier G.
In vivo fluorescence-mediated tomography for quantification of urokinase receptor-dependent leukocyte trafficking in inflammation.
Anesthesiology. 2010 Sep;113(3):610-8
25. Eisenbl tter M, H ltke C, Persigehl T, **Bremer C**.
Optical techniques for the molecular imaging of angiogenesis.
Eur J Nucl Med Mol Imaging. 2010 Aug;37 Suppl 1:S127-37. Review
26. Persigehl T, Wall A, Kellert J, Ring J, Remmele S, Heindel W, Dahnke H, **Bremer C**.
Tumor blood volume determination by using susceptibility-corrected ΔR_2^* multiecho MR.
Radiology. 2010 Jun;255(3):781-9
27. Schw ppe C, Kessler T, Persigehl T, Liersch R, Hintelmann H, Dreischal ck J, Ring J, **Bremer C**, Heindel W, Mesters RM, Berdel WE
Tissue-factor fusion proteins induce occlusion of tumor vessels.
Thromb Res. 2010 Apr;125 Suppl 2:S143-50



28. Höltke C, Faust A, Breyholz HJ, Kopka K, Schober O, Riemann B, **Bremer C**, Schäfers M, Wagner S
Non-invasive approaches to visualize the endothelin axis in vivo using state-of-the-art molecular imaging modalities.
Mini Rev Med Chem. 2009 Dec;9(14):1580-95. Review
29. Bunck AC, Engelen MA, Schnackenburg B, Furkert J, **Bremer C**, Heindel W, Stypmann J, Maintz D
Feasibility of functional cardiac MR imaging in mice using a clinical 3 Tesla whole body scanner.
Invest Radiol. 2009 Dec;44(12):749-56
30. Höltke C, Law MP, Wagner S, Kopka K, Faust A, Breyholz HJ, Schober O, **Bremer C**, Riemann B, Schäfers M
PET-compatible endothelin receptor radioligands: synthesis and first in vitro and in vivo studies.
Bioorg Med Chem. 2009 Oct 15;17(20):7197-208
31. Eisenblätter M, Ehrchen J, Varga G, Sunderkötter C, Heindel W, Roth J, Bremer C, Wall A.
In vivo optical imaging of cellular inflammatory response in granuloma formation using fluorescence-labeled macrophages.
J Nucl Med. 2009 Oct;50(10):1676-82. Epub 2009 Sep 16
32. Faust A, Waschkau B, Waldeck J, Höltke C, Breyholz HJ, Wagner S, Kopka K, Schober O, Heindel W, Schäfers M, **Bremer C**
Synthesis and Evaluation of a Novel Hydroxamate Based Fluorescent Photoprobe for Imaging of Matrix Metalloproteinases.
Bioconjug Chem. 2009 May 20;20(5):904-12
33. Herrmann E, Tiemann A, Eltze E, Bolenz C, **Bremer C**, Perisgehl T, Hertle L, Wülfing C
Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model.
J Cancer Res Clin Oncol. 2009; 135(10):1455-62
34. Bieker R, Kessler T, Schwöppe C, Padro T, Perisgehl T, **Bremer C**, Dreischalück J, Kolkmeier A, Heindel W, Mesters RM, Berdel WE
Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
Blood. 2009 May 14;113(20):5019-27
35. Höltke C, Greese S, Waldeck J, Kopka K, Heindel W, Schäfers M, **Bremer C**
Biodistribution of a nonpeptidic fluorescent endothelin A receptor imaging probe.
Mol Imaging. 2009 Jan-Feb;8(1):27-34
36. Waldeck J, Häger F, Höltke C, Lanckohr C, von Wallbrunn A, Torsello G, Heindel W, Theilmeier G, Schäfers M, **Bremer C**
Near infrared fluorescence imaging of atherosclerotic plaques using an alpha(v)beta(3)-integrin targeted fluorochrome.
J Nucl Med. 2008 Nov;49(11):1845-51
37. Buerke B, Allkemper T, Kugel H, **Bremer C**, Evers S, Kooijman H, Heindel W, Tombach B
Qualitative and quantitative analysis of routinely postprocessed (CLEAR) CE-MRA data sets: Are SNR and CNR calculations reliable?
Acad Radiol, 2008 Sep;15(9):1111-7



38. Sutton E, Henning T, Pichler B, **Bremer C**, Daldrup-Link HE
Cell Tracking with Optical Imaging.
Eur Radiol. 2008 8(10):2021-32
39. Faust A, Waschkau B, Waldeck J, Breyholz HJ, Kopka K, Heindel W, Schäfers M, **Bremer C**
Synthesis and Evaluation of a Novel Fluorescent Photoprobe for Imaging Matrix Metalloproteinases MMP-2 and MMP-9.
Bioconjug Chem. 2008 May;19(5):1001-8
40. Von Wallbrunn A, Waldeck J, Hoeltke C, Zühlsdorf M, Heindel W, Schäfers M, **Bremer C**
In vivo optical imaging of CD13/APN - expression in tumor xenografts.
J Biomed Opt, 13(1):011007 (2008)
41. Wall A, Persigehl T, Hauff P, Licha K, Schirner M, Müller SA, von Wallbrunn A, Matuszewski L, **Bremer C**
Differentiation of angiogenic burden in human breast cancer xenografts using a new perfusion type optical contrast agent (SIDAG).
Breast Cancer Res, 10;10(2):R23 (2008)
42. Stelljes M, Hermann S, Albring J, Kohler G, Loffler M, Franzius C, Poremba C, Schlosser V, Volkmann S, Opitz C, **Bremer C**, Kucharzik T, Silling G, Schober O, Berdel WE, Schaefers M, Kienast J.
Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction and monitoring of treatment efficiency by positron emission tomography.
Blood, 1;111(5):2909-18 (2008)
43. Thoennissen NH, Schliemann C, Brunberg U, Schmidt E, Staebler A, Stegger L, **Bremer C**, Schleicher C, Mesters RM, Müller-Tidow C, Berdel WE.
Chemotherapy in metastatic malignant triton tumor: report on two cases.
Oncol Rep. 18(4):763-7 (2007)
44. Persigehl T, Matuszewski L, Kessler T, Wall A, Meier N, Ebert W, Berdel W, Heindel W, Mesters RM, **Bremer C**
Prediction of anti-angiogenic treatment efficacy by iron oxide enhanced parametric MRI.
Inv Radiol, 42(12):791-6 (2007)
45. Persigehl T, Bieker R, Matuszewski L, Wall A, Kessler T, Kooijman H, Meier N, Ebert Berdel W, Heindel W, Mesters RM, **Bremer C**
Early, non-invasive monitoring of anti-angiogenic tumor treatment by USPIO enhanced MRI in mice.
Radiology, 244(2):449-56 (2007)
46. Kuhlper R, Dahnke H, Matuszewski L, Persigehl T, von Wallbrunn A, Allkemper T, Heindel W, Schaeffter T, **Bremer C**
R2/R2* mapping for sensing cell bound superparamagnetic nanoparticles.
Radiology, 245(2):449-57 (2007)
47. Holtke C, Von Wallbrunn AV, Kopka K, Schober O, Heindel W, Schäfers M, **Bremer C**
A Fluorescent Photoprobe for the Imaging of Endothelin Receptors.
Bioconjug Chem, 18(3):685-94 (2007)



48. Matuszewski L, Tombach B, Heindel W, **Bremer C**
Molekulare und parametrische Bildgebung mit Eisenoxiden.
Radiologe, 47:34-42 (2007)
49. Von Wallbrunn A, Holtke C, Zuhlsdorf M, Heindel W, Schafers M, **Bremer C**
In vivo imaging of integrin $\alpha_3\beta_1$ expression using fluorescence-mediated tomography
Eur J Nucl Med Mol Imaging, 34:745-754 (2007)
50. Matuszewski L, Persigehl T, Wall A, Meier N, Bieker R, Kooijmann H, Tombach B, Mester R, Berdel W, Heindel W, **Bremer C**
Assessment of Bone Marrow Angiogenesis in patients with Acute Myeloid Leukaemia by Contrast Enhanced MRI with clinically approved iron oxides.
Radiology, 242:217-224 (2007)
51. Albrecht O, Serve H, Tchinda J, Büchner T, **Bremer C**, Parwaresch R, Berdel WE
Acute Myeloid Leukemia presenting with a Uterus Tumor.
Ann Hematol, 85:58-59 (2006)
52. Hölteke C, Law M, Wagner S, Breyholz H-J, Kopka K, Bremer C, Schober O, Schäfers
Synthesis, in vitro pharmacology and biodistribution studies of new PD 156707-derived ET_A receptor radioligands.
Bioorg Med Chem, 14:1910-1917 (2006)
53. Kessler T, Bieker R, Padró T, Schwöppe C, Persigehl T, **Bremer C**, Kreuter M, Berdel W, Mesters R
Inhibition of Tumor Growth by RGD Peptide Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature.
Clin Cancer Res, 11:6317-6324 (2005)
54. **Bremer C**, Ntziachristos V, Weitkamp B, Theilmeier G, Heindel W, Weissleder R
Optical imaging of spontaneous breast tumors using protease sensing 'smart' optical contrast agents.
Invest Radiol 40(6): 321-7 (2005)
55. **Bremer C**, Bankert J, Filler T, Tombach B, Ebert W, Reimer P
High-dose Gd-DTPA versus Gd-mesoporphyrin for postinterventional monitoring of LITT-induced tissue necrosis.
JMIR, 21(6), 801-8 (2005)
56. Juergens KU, Reimer P, Weber TP, Tombach B, **Bremer C**, Renger B, van Aken H, Heindel W
Cine and tagged magnetic resonance imaging in short-term stunned versus necrotic myocardium?
Int J Cardiovasc Imaging, 21(2-3) 271-82 (2005)
57. Persigehl T, Heindel W, **Bremer C**
MR and optical approaches to Molecular Imaging.
Abdom Imaging, 30(3):342-54 (2005)
58. Matuszewski L, Persigehl T, Wall A, Schwindt W, Tombach B, Fobker M, Poremba C, Ebert W, Heindel W, **Bremer C**
Cell Tagging with clinically approved iron oxides: Feasibility and effect of lipofection, particle size and surface coating on labeling efficiency.
Radiology, 235(1): 155-61 (2005)



59. Tombach B, Reimer P, **Bremer C**, Allkemper T, Engelhardt M, Mahler M, Ebert W, Heindel W
First pass- and equilibrium- MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): Results of a human pilot study.
NMR Biomed, 2004 Nov;17(7):500-6.
60. Reimer P, **Bremer C**, Allkemper T, Engelhardt M, Mahler M, Ebert W, Tombach B
Myocardial Perfusion and MR Angiography of Chest with SH U 555 C: Results of Placebo-controlled Clinical Phase I Study.
Radiology 231(2): 474-81 (2004)
61. Wunderbaldinger P, Turetschek K, **Bremer C**
Near-infrared fluorescence imaging of lymph nodes using a new enzyme sensing activatable macromolecular optical probe.
Eur Radiol. 13(9): 2206-2211 (2003)
62. Kugel H, **Bremer C**, Puschel M, Fischbach R, Lenzen H, Tombach B, Van Aken H, Heindel W
Hazardous situation in the MR bore: induction in ECG leads causes fire.
Eur Radiol. 13(4):690-4 (2003)
63. **Bremer C**, Ntziachristos V, Weissleder R
Optical based Molecular Imaging: Contrast agents and potential medical applications.
Eur Radiol, 13(2):231-43 (2003)
64. Ntziachristos V, **Bremer C**, Weissleder R
Fluorescence imaging with near infrared-light: new technological advances that enable in-vivo molecular imaging.
Eur Radiol, 13(1):195-208 (2003)
65. **Bremer C**, Mustafa M, Bogdanov A, Ntziachristos V, Petrovsky A, Weissleder R
Steady state blood volume measurements in experimental tumors differing in angiogenic burden.
Radiology, 226(1):214-20 (2003)
66. **Bremer C**, Tung CH, Weissleder R
Molecular imaging of MMP expression and therapeutic MMP inhibition.
Acad Radiol 9 Suppl 2:S314-5 (2002)
67. Ntziachristos V, **Bremer C**, Tung C, Weissleder R.
Imaging cathepsin B up-regulation in HT-1080 tumor models using fluorescence-mediated molecular tomography (FMT).
Acad Radiol 9 Suppl 2:S323-5 (2002)
68. Ntziachristos V, **Bremer C**, Graves EE, Weissleder R
In-vivo tomographic imaging of near-infrared fluorescent probes.
Mol Imaging 1 (2), 82-88 (2002)
69. Bogdanov A, Matuszewski L, **Bremer C**, Petrovsky A, Weissleder R
Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets.
Mol Imaging 1 (1), 16-23 (2002)



70. Ntziachristos V, Tung C-H, **Bremer C**, Weissleder R
Fluorescence-mediated tomography resolves protease activity in vivo.
Nature Medicine 8 (7), 757-60 (2002)
71. Marten K, **Bremer C**, Khazaie K, Tung C-H, Weissleder R
Detection of dysplastic intestinal adenomas using enzyme sensing molecular beacons.
Gastroenterology 122 (2), 406-14 (2002)
72. Wunderbaldinger P, **Bremer C**, Schellenberger E, Cejna M, Turetschek K, Kainberger
Imaging features of iliopsoas bursitis.
Eur Radiol 12 (2), 409-15 (2002)
73. Tombach B, **Bremer C**, Reimer, Kisters K, Schaefer RM, Geens, W, Heindel W
Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring
hemodialysis: safety and dialysability.
Am J Roentgenol 178 (1), 105-9 (2002)
74. Wunderbaldinger P, Josephson L, **Bremer C**, Moore A, Weissleder R
Detection of lymph node micrometastases by LCDIO enhanced MR imaging.
Magnetic Resonance in Medicine 47 (2), 292-7 (2002)
75. Allkemper T, **Bremer C**, Matuszewski L, Ebert W, Reimer P
Contrast-enhanced blood pool MRA with optimized iron oxides: Effect of size, relaxivity,
and dose on vascular contrast enhancement.
Radiology 223 (2), 432-8 (2002)
76. **Bremer C**, Kreft G, Filler T, Reimer P
Accuracy of non-enhanced MRI to monitor histological lesion size during laser-induced
interstitial thermotherapy.
Eur Radiol 12 (1), 237-44 (2002)
77. **Bremer C**, Tung C-H, Bogdanov A, Weissleder R
Imaging of differential protease expression in breast cancers for detection
of aggressive tumor phenotypes.
Radiology 222 (3), 814-8 (2002)
78. **Bremer C**, Bredow S, Mahmood U, Weissleder R, Tung CH
Optical imaging of Matrix Metalloproteinase-2 activity in tumors: Feasibility study in a
mouse model.
Radiology 221 (2), 523-9 (2001)
79. **Bremer C**, Kreft G, Roggan A, Filler T, Reimer P
Ex vivo evaluation of novel miniaturized LITT-applicators for effective small volume
tissue ablation.
Invest Radiol 36 (6), 32-34 (2001)
80. Wunderbaldinger P, **Bremer C**, Matuszewski L, Marten K, Turetschek K, Rand T
Efficient radiological assessment of the internal snapping hip syndrome.
Eur Radiol 11(9), 1743-7 (2001)
81. Tombach B, **Bremer C**, Reimer, Kisters K, Schaefer RM, Geens, W, Heindel W
Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal
failure: Results of a randomized study.
Radiology 218 (3), 651-7 (2001)



82. **Bremer C**, Tung C, Weissleder R
In vivo molecular target assessment of matrix metalloproteinase inhibition
Nature Medicine 7 (6), 743-48 (2001)
83. Filler T, **Bremer C**, Peuker E, Bankert J, Kreft G, Reimer P
Hepatomorphologie der Laser-induzierten interstitiellen Thermotherapie.
Radiologe 41 (2), 181-186 (2001)
84. **Bremer C**, Bogdanov A, Weissleder R
Bildgebung von Angiogenese.
Radiologe 41 (2), 138-145 (2001)
85. **Bremer C**, Ntziachristos V, Mahmood U, Tung C-H, Weissleder R
Fortschritte in der optischen Bildgebung.
Radiologe 41 (2), 131-137 (2001)
86. **Bremer C**, Weissleder R
In vivo imaging of gene expression: MR and optical technologies.
Acad Radiol 8, 15-23 (2001)
87. Tombach B, **Bremer C**, Reimer P, Schaefer RM, Ebert W, Geens V, Heindel W
Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure .
Invest Radiol 35 (1), 35-40 (2000)
88. Tombach B, Reimer P, Prumer B, Allkemper T, **Bremer C**, Muhler A, Heindel W
Does a higher concentration of gadolinium chelates improve first-pass cardiac signal changes?
JMRI 10 (5), 806-12 (1999)
89. **Bremer C**, Allkemper T, Bärmig J, Reimer P
RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography.
JMRI 10 (3), 461-7 (1999)
90. Franzius C, Sciuk J, **Bremer C**, Kempkes M, Schober O
Determinaton of extent and activity in Erdheim-Chester disease.
Clin Nucl Med 24 (4), 252-55 (1999)
91. Cullen P, Söffker J, Höpfl M, **Bremer C**, Schlaghecken R, Mehrens T, Assmann G, Schäfer RM.
Hypochromic red cells and reticulocyte haemoglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis.
Nephrol Dial Transplant 14 (3), 659-65 (1999)
92. Reimer P, **Bremer C**, Horch C, Morgenroth C, Allkemper T, Schuierer G
MR-Monitored LITT as a palliative concept in patients with high grade gliomas: Preliminary clinical experience.
JMRI 8, 240-244 (1998)
93. **Bremer C**, Allkemper Th, Menzel J, Sulkowski U, Rummeny E, Reimer P
Preliminary clinical experience with laser-induced interstitial thermotherapy in patients with hepatocellular carcinoma.
JMRI 8, 235-239 (1998)



94. Kribben A, **Bremer C**, Fritschka E, Koeppen S, Ahrens O, Philipp T
Ambulatory infusion of noradrenaline for long-term treatment of Shy-Drager syndrome.
Kidney Blood Press Res 21 (1), 70-3 (1998)
95. **Bremer C**, Schaefer R M
Heterozygosity for factor V Leiden in a haemodialysis patient with recurrent shunt
thrombosis.
Nephrol Dial Transplant 12 (8), 1775-1776 (1997)
96. Reimer P, Allkemper T, **Bremer C**, Rummeny E J, Spiegel H U, Balzer T, Peters P E
Assessment of reperfusion injury by means of MR contrast agents in rat liver.
JMRI 7, 490-494 (1997)
97. Spiegel H U, Oldhafer K, Lang W, Schüttler W, **Bremer C**, Pichlmayr R
Beneficial effect of PAF antagonist WEB 2170 on reperfusion injury after orthotopic liver
transplantation.
Transplant Proc 27 (5), 2849-2851 (1995)
98. **Bremer C**, Allkemper T, Reimer P, Rummeny E J, Spiegel H U, Peters P
Contrast enhanced MRI with intracellular contrast agents –
A new way of monitoring hepatic reperfusion injury?
Transplant Proc 27 (5), 2884-2885 (1995)
99. Spiegel H U, **Bremer C**, Boin C
Reduction of hepatic reperfusion injury by indomethacin mediated vasoconstriction:
A rat model with temporary splenocaval shunt.
J Invest Surg. 8, 363-369 (1995)
100. Bremer C, Bradford B U, Hunt K J, Knecht K T, Connor H D, Mason R P, Thurman R G
Role of Kupffer cells in the pathogenesis of hepatic reperfusion injury.
Am J Physiol 267 (30), G630 - G636 (1994)



Buchbeiträge

1. **Bremer C**
Molecular targets, Reporter systems, Molecular probes, optical probes
In: Baert A L
Encyclopedic Reference of Imaging, Springer Verlag, (2009)
2. **Bremer C**, Schäfers M
Targets
In: Bombardieri E, Buscombe J, Lucignani G, Schober O
Advances in Nuclear Oncology, (2009)
3. Wall A, **Bremer C**
Optical imaging techniques for breast cancer
In: Hyat MA
Cancer imaging – lung and breast cancer
Elsevier Verlag, Amsterdam (2008)
4. Wunder A, Kloh J, **Bremer C**
Molekulare Bildgebung mit optischen Methoden – Möglichkeiten und Grenzen
In: W. Niederlag (Dresden), H. U. Lemke (Berlin), W. Semmler (Heidelberg), **C. Bremer** (Münster). Molecular Imaging – Innovationen und Visionen in der medizinischen Bildgebung. Health Academy, Dresden (2006)
5. **Bremer C**
Imaging of proteases for tumor detection and differentiation
In: Bogdanov A, Licha K. Ernst Schering Res Found Workshop 49: Molecular Imaging, an essential tool in preclinical research, diagnostic imaging and therapy. Springer Verlag, Heidelberg (2005)
6. Tombach B, Buerke B, Persigehl T, **Bremer C**
Kontrastmittel
In: Brambs HJ: Radiologie update ,04. MPM Verlag, Pohlheim (2004)
7. **Bremer C**, Weissleder R
The role of nuclear medicine in relation to alternative modalities.
In: Feinendegen LE, Shreeve WW, Bahk YW, Wagner Jr HN: Molecular Nuclear Medicine. The Challenge of genomics and proteomics to clinical practice. Springer Verlag, Heidelberg (2003)
8. **Bremer C**, Weissleder R
In Vivo Optical Imaging. In: Lorkowski S, Cullen P: Analyzing Gene Expression Wiley-VHC Verlag, Weinheim (2002)
9. **Bremer C**, Weissleder R
Magnetic Resonance Imaging at the mRNA and Protein Level.
In: Lorkowski S, Cullen P: Analyzing Gene Expression Wiley-VHC Verlag, Weinheim (2002)
10. **Bremer C**
Abdomen - MR-gesteuerte Interventionen
In: Rummeny E, Reimer P, Heindel W: Ganzkörper MRT. Thieme Verlag, Heidelberg (2002)



11. **Bremer C**
Interventionelle MRT
In: Reimer P, Parizel P M, Stichnoth F A: Klinische MR-Bildgebung. Springer Verlag, Heidelberg (2000)

12. **Bremer C**
Interventional MR
In: Reimer P, Parizel P M, Stichnoth F A: Clinical MR-Imaging - A Practical Approach. Springer Verlag, Heidelberg (1999)